Unsolved challenges of clinical whole-exome sequencing: a systematic literature review of end-users’ views by unknown
RESEARCH ARTICLE Open Access
Unsolved challenges of clinical whole-exome
sequencing: a systematic literature review of
end-users’ views
Gabrielle Bertier1,2* , Martin Hétu1 and Yann Joly1
Abstract
Background: Whole-exome sequencing (WES) consists in the capture, sequencing and analysis of all exons in the
human genome. Originally developed in the research context, this technology is now increasingly used clinically to
inform patient care. The implementation of WES into healthcare poses significant organizational, regulatory, and ethical
hurdles, which are widely discussed in the literature.
Methods: In order to inform future policy decisions on the integration of WES into standard clinical practice,
we performed a systematic literature review to identify the most important challenges directly reported by
technology users.
Results: Out of 2094 articles, we selected and analyzed 147 which reported a total of 23 different challenges
linked to the production, analysis, reporting and sharing of patients’ WES data. Interpretation of variants of
unknown significance, incidental findings, and the cost and reimbursement of WES-based tests were the most
reported challenges across all articles.
Conclusions: WES is already used in the clinical setting, and may soon be considered the standard of care
for specific medical conditions. Yet, technology users are calling for certain standards and guidelines to be
published before this technology replaces more focused approaches such as gene panels sequencing. In addition, a
number of infrastructural adjustments will have to be made for clinics to store, process and analyze the amounts of
data produced by WES.
Background
Whole-exome sequencing (WES) consists in the capture,
sequencing and analysis of all exons of all protein coding
genes in the human genome. Instead of analyzing the
whole genome, composed of roughly 3 billion base-pairs,
WES focuses only on the approximately 30 million base-
pairs which are translated into functional proteins, in
which mutations are the most likely to have a severe
direct phenotypic consequence. WES can therefore be
considered a much less costly and more efficient
method of identifying all possible mutations in genes,
compared to other methods such as genome-wide associ-
ation studies or whole-genome sequencing (WGS) [1].
WES was originally used mainly to identify rare mutations
contributing to Mendelian diseases, as compared with the
many variants involved in common complex diseases [2],
although this distinction can be considered artificial [3].
Methodologies evolve rapidly, and new software enable
this technology to better detect complex genetic changes
such as structural variants [4] and copy-number variants
[5–7]. The integration of WES into healthcare is already
underway, contributing to the development of personal-
ized medicine [2]. It is currently used clinically for numer-
ous purposes, ranging from diagnosis to disease prognosis
and treatment decisions [8]. Analysing a patient’s exome
through one test is now less costly than testing a number
of specific genes, especially when little is known about the
genetic background of the disease, although this analysis
does “add layers of complexity to test interpretation” [9].
In addition to the technical challenges of making the tech-
nology fit for clinical diagnostics (improving exon capture,
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sequencing coverage, read length, accurate detection
of insertion-deletions, and reduction of false positive
and false negative rates), numerous hurdles have to
be overcome to use WES in routine healthcare. A
number of ethical, legal, social and policy challenges
have been extensively discussed in the literature by scien-
tific researchers as well as policymakers and professional
societies [10–15]. Guidelines have been produced to re-
spond to some of these challenges, notably that of report-
ing incidental findings (IF). The American College of
Medical Genetics and Genomics (ACMG) published a
policy recommendation on this topic in 2013 [16], which
has been heavily discussed [17–20], and updated in 2014
[21]. The European Society of Human Genetics, in turn,
published a recommendation in 2015 [22]. The Canadian
College of Medical Geneticists published a position
statement in 2015 to frame the “clinical application of
genome-wide sequencing for monogenic diseases in
Canada” [23]. But in order to design efficient policies
aimed at enabling the responsible integration of WES into
healthcare, there is the need to systematically identify
what the prominent challenges are. To our knowledge no
study has yet been published on the implementation hur-
dles identified directly by scientific researchers and med-
ical doctors (technology users) reporting on the clinical
use of WES. With this objective in mind, we designed a
systematic review of the literature to identify the most im-
portant challenges directly reported by technology users.
Methods
Our systematic literature review methodology was adapted
from the PRISMA guidelines [24] and the Petticrew and
Roberts practical guide [25]. The completed PRISMA flow
diagram and PRISMA checklist, as well as the full articles
dataset are available in Additional files 1, 2 and 3.
Studies sources
6 databases were searched to identify the most compre-
hensive list of publications. The last search was per-
formed on March 31st, 2015.




3. NCBI Pubmed http://www.ncbi.nlm.nih.gov/
pubmed/
4. Science Direct http://www.sciencedirect.com/
5. Scopus http://www.scopus.com/
6. Web of Science http://apps.webofknowledge.com/
Choice of keywords
Since our objective was to identify reports published by
technology users on the clinical use of WES, we used
the following keywords in combination to stringently fil-
ter out reports from outside the clinical context: Clinical
application, Medical application, Healthcare, Clinical
care, Medical care, Clinical practice, Clinical diagnostic,
Medical practice.
Therefore, the complete search used was the following:
(“exome sequencing” OR “whole-exome sequencing”
OR “whole exome sequencing”) AND (“clinical applica-
tion” OR “medical application” OR “healthcare” OR “clin-
ical care” OR “medical care” OR “clinical practice” OR
“clinical diagnostic” OR “medical practice”).
Screening, filtering and selection
We searched for the chosen keywords using the full text
of articles and reports without any date or language re-
strictions. The search resulted in 2275 articles (details
available in Table 1). All results were then aggregated in
a single Excel file, from which we removed duplicates,
resulting in 2094 unique articles.
Further screening was done in two steps:
– First, we screened out results that were not peer
reviewed journal articles (such as abstracts from
conference oral presentations or posters, blog articles,
or conference programs).
– We then removed articles that were not written in
English, French or Spanish.
At this point, both GB and MH processed with filter-
ing the articles in parallel, according to the following in-
clusion and exclusion criteria:
– The articles are written by a technology user,
defined as a medical doctor, life science researcher
or medical researcher who is directly exposed to the
technology in his field of expertise. At this point we
excluded articles for which the corresponding
author was a researcher in policy or human and
social sciences.
– The articles directly address WES. At this point we
excluded articles which, for instance, simply referred
Table 1 Total number of hits by database
Database searched Total hits





Web of Science 119
TOTAL 2275
Total unique articles 2094
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to other studies which had used WES. We included
articles that talked about other technologies in
addition to WES, such as WGS or gene panels.
– The articles discuss the clinical implementation of
WES. At this point we excluded articles which only
considered WES in the context of basic research or
discovery.
– The articles list unsolved implementation challenges.
We excluded articles which did not mention any
challenge linked to the clinical implementation of
WES, which listed challenges already solved, or
which described them as easy to solve through
measures already partly in place. We also excluded
articles which we tagged as ‘recommendations’ when
they consisted of a list of solutions for the clinical
implementation of WES and did not describe any
challenge or issue as ‘unsolved’.
After filtering all articles separately, GB and MH com-
pared their selected articles list, discussed any articles se-
lected only by one of them, and agreed on a final
decision for each of those articles. Only 10 % of articles
required discussion (182 out of 1792 articles).
The full list of selected articles is available in Additional
file 1. The results of all screening and filtering steps are
described in Table 2.
Coding
Since our objective was to be as comprehensive and
unbiased as possible in the identification of unsolved
challenges relevant to technology users, the coding of
articles was done through inductive content analysis
[26, 27]. An initial list of challenges was generated by
GB on the basis of an analysis of 30 articles selected
at random (20 % of all selected articles). These challenges
were then discussed and adjusted by all co-authors to-
gether. Some similar challenges were merged, while others
were split into separate challenges. Additional challenges
were added both by MH and GB over the course of the
analysis if five articles or more were found to refer to any
specific challenge. For the data analysis, we decided to
group challenges along a typical ‘timeline’ ranging from




The first articles selected were published in 2010, which
is consistent with the appearance of WES technology in
the scientific literature. 3 articles (2 %) were published in
2010, 13 (9 %) in 2011, 31 (21 %) in 2012, 42 (29 %) in
2013, and 46 (31 %) in 2014 and 12 (8 %) in the first tri-
mester of 2015, when we performed the search.
Whole-exome sequencing/Next-generation sequencing/
High-throughput sequencing
Among the selected articles, only 48 (34 %) focused
exclusively on WES. The other 94 articles either discussed
challenges linked to other technologies such as WGS or
large gene panels, or discussed challenges linked to Next-
Generation Sequencing or High Throughput Sequencing
(including WES and other technologies) in general.
Article types
A graph representing all article types is available in Fig. 1.
Of the selected 147 articles, the vast majority (106,
72 %) are review articles in which the authors do not re-
port directly on the way they personally use WES, but
rather review the current body of evidence about a cer-
tain aspect of the technology. The majority of review ar-
ticles (66, 62 % of reviews) describe the impact of WES
on a specific disease or disease group, and 5 (5 % of re-
views) generally discuss its use in the diagnosis of vari-
ous diseases, whereas 25 (23 % of reviews) review the




Removing duplicates 2094 181
Peer reviewed journal articles 1810 284
















Fig. 1 Selected articles types. Review: the authors do not report
directly on the way they personally use WES, but rather review the
current body of evidence about a certain aspect of the technology.
Application: authors report on the application of WES on a specific
patient, family, or a larger group of patients in a healthcare service.
Data analysis: authors focus on challenges linked with WES data
processing, analysis and interpretation. Efficiency: authors compare
the efficiency of WES compared to other techniques, such as gene
or gene panels sequencing. Report: authors report on the use of a
technology other than WES, and explain this choice by identifying
challenges with WES
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technology in general, including both its research and
clinical applications. 6 articles (6 % of reviews) describe
how the technology may impact a specific medical field,
such as nursing [28] or pathology [29] while 4 (4 % of
reviews) focus on pharmacogenomic applications. 12 ar-
ticles (8,2 %) report directly on applications of the tech-
nology for a specific patient [30, 31], a family [32], a
selected group of patients [33–35], or on a larger scale
for a particular healthcare service [36–41]. 8 articles
(5.4 %) discuss the efficiency of WES compared to other
techniques, such as gene panels or WGS. 6 articles (4 %)
report on the use of a technology other than WES, and
explain this choice by identifying challenges with WES.
Finally, 8 articles (5,4 %) focus on challenges linked with
WES data processing, analysis and interpretation.
Disease focus
Our first observation was that the articles selected cover
an extremely wide range of diseases, from cancer (26,
29 %) to rare diseases (24, 16.3 %) to common disorders
such as intellectual disability and developmental delay
(6, 4 %). 14 (9.5 %) articles focus on a diversity of heart
diseases, 13 (14 %) on neurological diseases, and 3 (2 %)
respectively on blood, muscle, and kidney disorders. It is
a particularly challenging task to group the diseases ad-
dressed by our selection of articles in relevant categories
for three main reasons. Firstly, those categories may
partly overlap: for instance, cancer in children is consid-
ered to be a rare disease. Secondly, a number of articles
(9, 6 %) focus generally on genetic or inherited disorders,
which may or may not be rare diseases. Thirdly, some
articles cover many possible diseases – such as cancer
[42, 43] or rare diseases [44, 45] in general - while others
focus specifically on one disease [46–48]. A significant
number of articles (42, 29 %) did not focus on any
diseases in particular, but addressed the impact of WES
on all clinical contexts.
Country
We noted the country of the institution of corresponding
authors of all selected articles. A total of 19 countries were
represented. The majority of articles (92, 62 %) we se-
lected were written in the USA. 25 (17 %) were written in
Continental Europe (excluding the UK, which represented
an additional 13 articles). The complete distribution of ar-
ticles per country is represented in Fig. 2.
Number of challenges covered
On average, the 147 selected articles covered 8 of the
identified challenges. The majority of articles (90, 61.2 %)
covered from 1 to 5 challenges. 47 articles (32 %) covered
between 6 and 10 challenges, and only 10 articles (6.8 %)
covered more than 10 challenges. This steadily decreasing
distribution shows the importance of the systematic re-
view methodology in identifying all challenges linked to
the clinical implementation of WES as identified by tech-
nology users. This distribution is displayed in Fig. 3.
Unsolved challenges identified
From the original 147 studies, we identified 23 unsolved
challenges. These were divided into 4 categories, follow-
ing the ‘samples and data trajectory’, of production, ana-
lysis, reporting and sharing.
Table 3 briefly describes the challenges found in all
articles. Figure 4 displays the total number of articles
covering each challenge. The unsolved challenges re-
ported by technology users are extremely diverse,
ranging from very specific challenges, such as the inclu-
sion of WES results in patients electronic health records,
to much broader ones, such as the challenges of
Fig. 2 Number of articles per country of institution of corresponding author
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communicating results with patients and their families and
managing their expectations. Three challenges (henceforth
referred to as major challenges) were reported by more
than 70 (47,6 %) articles:
– the interpretation of variants and variants of
unknown significance (VUS) was reported by 92
(62.6 %) articles
– challenges linked to incidental findings were
reported by 79 (53.7 %) articles
– the cost of WES and reimbursement of the test by
the healthcare system was reported by 72 (49 %)
articles.
The following sections provide an overview of the
terms in which these three challenges are described in
the selected articles.
Data analysis challenge: variants of unknown/uncertain
significance (VUS)
The most important challenge mentioned by the se-
lected articles was that of the lack of standards and the
complexity of variants interpretation, along with the
high risk of finding VUS, which Sutton et al., 2012 con-
sider a ‘plague’ to the field of clinical WES [49]. Unlike
targeted single gene or gene panel sequencing assays,
WES usually generates a long list of mutations, a large
number of which have no known significance. VUS are
reported to represent the majority of variants identified
by next-generation sequencing (NGS) technologies such
as WES [38, 50], although much fewer VUS are found in
WES than in WGS [51]. It is unsurprising that VUS is
the most consistently reported challenge, as it lies at the
heart of a network of connected challenges. The assess-
ment of VUS' pathogenicity is a long, complex and ex-
pensive research process [52], which requires the
collaborative intervention of different highly trained spe-
cialists [53] including bioinformaticians, biologists and
clinicians [54]. This need for interdisciplinary collabor-
ation, along with the way WES testing may challenge
existing professional roles in the clinic, was reported as
a challenge by 50 (34 %) articles. To interpret variants,
these specialists rely on bioinformatics analysis pipelines
made of imperfect algorithms [36, 37, 42, 55], referring
to imperfect databases [44, 50, 56, 57]. The need to de-
velop more efficient and standardised bioinformatics
tools to filter, analyze and interpret WES variants was
reported as a challenge by 44 (29.29 %) articles. The
need to share NGS results and to develop more
complete, less biased databases containing fewer false
positive and false negative variant-phenotype associa-
tions was identified as a challenge in 40 (27.2 %) articles.
As described by Jongbloed et al., [58], the “only reason-
able way to deal with [the ascertainment of VUS] is to
pursue maximum data dissemination in the scientific
community”, who could accelerate the analysis of VUS
by creating and sharing access to large scale databases
gathering sequencing results from as many studies as
possible. Certainly, the more sequencing results are
shared, the less likely it is that variants identified in pa-
tients will never have been reported before. This vision
is also shared by Xue et al. [50], who assert that “With
more individuals from different ethnic groups sequenced
through NGS, more rare variants will inevitably be re-
vealed”, and by Lin et al. [59]: “Sifting through the mil-
lions of variants in an individual’s genome for the
pathogenic mutation seems to be the most urgent task
at hand. The creation of dedicated databases specifically
for the purpose of clinical interpretation based on NGS
results from a large number of normal controls and di-
agnosed patients will significantly help this endeavor”.
Considering the current uncertainty involved in inter-
preting VUS, they can represent a heavy burden [60] if
reported to a patient’s genetic counsellor or physician.
Having access to this information may force clinicians to
make a ‘judgment call’ [61] in trying to interpret VUS,
and potentially report them to patients, which risks
causing them unnecessary anxiety [62]. This dilemma is
particularly prevalent in screening for mutations contrib-
uting to the genetic background of rare diseases. Indeed,
some genes are only found to be mutated in 1 or 2 fam-


































Fig. 3 Number of challenges covered across articles
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Table 3 Description of challenges identified
Category Challenge Description
Data production Patient selection It is difficult to determine which patients would receive a clear clinical advantage from WES.
First tier test It may not be clear whether WES should be used as a first tier test, or as a second tier test
after the failure of more selective genetic testing such as gene(s) or gene panel(s) testing.
Clinicians buy-in Some clinicians are not willing to order WES testing, sometimes because of lack of trust in
the technique. This can be an important barrier to clinical implementation of WES.
Sequencing facility Decisions will have to be made about whether sequencing should be done in each
laboratory offering the test, or if laboratories should order it from centralized sequencing
facilities.
Turnaround time WES results can sometimes take longer to obtain than more targeted tests, which may
challenge their implementation in a clinically relevant timeframe.
Data storage WES data requires a large and secure storage space, which may not always be available in a
clinical setting.
Gene patents In some jurisdictions, patents on the sequence of specific genes may make it difficult to
sequence whole exomes without having to pay IP rights.
Cost and reimbursement The cost of WES sequencing and analysis may be too high for some clinical applications.
Reimbursement strategies for such tests are yet to be established by private insurers and by
the healthcare systems.
CLIA/ISO certification WES has yet to be standardized in order to obtain CLIA and ISO certification, in the USA
and in Europe respectively. This certification is key for clinical implementation and
reimbursement of WES by the healthcare systems.
Data quality standards There is still no formal agreement on the appropriate quality standards to apply to the
technology so that it can be implemented in the clinic.
Data analysis Bioinformatics Analysis of WES results relies on a number of bioinformatics tools that have yet to be
perfected.
Variant interpretation, VUS WES generates a high number of variants per individual, a large proportion of which are still
of unknown significance. The extreme difficulty of interpreting these variants has created a
bottleneck in the clinical application of the technology.
Databases To better interpret variants, WES and more generally NGS results need to be broadly
shared. More complete and reliable reference databases linking variants to patients’
phenotypes need to be developed.
Interdisciplinary team The interpretation of variants relies on the collaboration of different professionals, including
medical doctors, bioinformaticians, biologists and clinical geneticists. Integration of WES
into the clinic may require that we reconsider the definition of new and established
professional roles in clinical hospitals.
Incidental findings WES has the potential to generate a high number of incidental findings. These may create
anxiety in patients and the need for costly follow-up procedures if reported.
Reporting Data reporting standards (IF) There is a pressing need to develop standards on which a large part of the community can
agree regarding whether and how to report IF to patients and their families.
Data reporting standards (VUS) There is a pressing need to develop consensus standards on when and how to report VUS
to patients and their families.
Pregnancy termination WES may enable the detection of mutations at a time when pregnancy termination is still
possible, which was not possible with prior technologies. This leads to the necessity to
develop new policy decisions which take into account the ethical justifications behind
offering pregnancy termination options for these conditions.
Education Increased use of WES in the clinic will mean that a growing number of healthcare
professionals will need to interpret these data, and therefore need to be educated in the
basics of genetics and genomics. This is not the case today, as very few medical staff
currently have genomics knowledge.
Communication with patients
and families
The amount and complexity of the data produced by WES complicates the task of healthcare
professionals who have to report WES results to patients. In specific circumstances, they may
also have a duty towards some of their patients’ family members. Many more types of results
will have to be explained, in longer and therefore more costly pre and post-test counselling
sessions.
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their pathogenicity and their exact impact on patients,
which also makes genetic counselling significantly more
challenging [63]. According to Rabbani et al. [64], this
should be carefully addressed in the consent form, and
discussed during the consent process. In Need et al.
[35], the decision was taken at the onset of the study to
not report any variants of ‘uncertain significance’ to the
patients, regardless of whether or not they were later
proven to have significance. In comparison, Ream et al.
[65] performed a pilot study in which the need to ex-
plain VUS to the families of 6 pediatric drug-resistant
epilepsy patients represented a significant challenge,
which led them to conclude that “WES may raise more
questions than it answers for some patients”.
Incidental findings (IF)
The challenge of IF was also consistently mentioned in
92 (53.7 %) of selected articles. IF can be defined as
information of clinical relevance which is found during
the WES data analysis and which is beyond the scope of
the original clinical condition for which the patient was
‘prescribed’ a WES test. According to Sankaran et al.
[57], the “identification of actionable, IF during genome-
wide DNA sequencing genetic studies is a major concern
of many patients, as well as health care providers”, and
this can “cause ethical and clinical dilemmas” [66]. The
topic of genomic IF is heavily discussed in the literature,
and two recently published reviews [67, 68] provide
strong evidence showing that there is a lack of consen-
sus on how to define, analyze, and report such variants
to patients and research participants. Within our selec-
tion of articles, for instance, Lyon et al. [69] consider the
term “IF” to be “misleading”. They prefer using the term
“secondary findings”, which they argue better represents
their importance and could help correct the view that
such findings do not require significant time and effort
Table 3 Description of challenges identified (Continued)
Sharing Data ownership/privacy Given that WES data is inherently identifying and provides some information on the present
and future health status of the proband and their families, several privacy and ownership
questions have to be resolved: Who owns WES data? How should the access and sharing of
this data be regulated?
Genetic discrimination The possibility for insurers or insurance companies to access WES data may lead to greater
discrimination against potential clients or employees based on their genetic background.
Electronic health records The correct interpretation of WES data often relies on accessing a complete description of
patients’ phenotypic characteristics, which would be greatly facilitated by consulting
electronic health records. However, before this can be done public health systems and
hospitals will have to decide whether WES results should be added to patients’ electronic
health records.
















Data reporting standards (IF)
Data reporting standards (VUS)
Pregnancy termination
Education
Communication with patients / families
Data ownership / privacy
Genetic discrimination
Electronic health records
Fig. 4 List of unsolved challenges and proportion of articles reporting on them. We highlighted the challenges found in more than 40 % articles
(58 total) in red, and challenges found in 30 to 40 % articles (44 to 58) in green
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to be analyzed, interpreted, and reported. In 2013,
Sankaran et al. [57] stated that there was no consen-
sus on just how frequently they are actually found in
NGS data. However, several authors provide different
estimates: in 2014, Xue et al. [50] provided references
to support the claim that “the rate of reportable IFs
can range from 1 to 8.8 %”, while Gecz et al. [70] argued
that they range from 1 to 2 % of patients. Regardless of
how often IF are found in practice, they have to be
addressed in the patient pre-test counselling process
[51, 71], and this ‘intensive genetic counseling’ [28]
can be a “main issue” in practice [40, 72]. Incidental
findings are viewed as a potential “additional burden”
[65] and source of anxiety for patients and their fam-
ilies [62, 73, 74].
19 out of the 55 articles published since 2013 which
mention IF as a challenge (34.5 %) refer to the American
College of Medical Genetics and Genomics (ACMG)
recommendation on reporting IF [16, 21]. This recom-
mendation, which provides a list of 56 genes to be sys-
tematically searched for ‘actionable variants’, has clearly
raised “concerns” [53] and debate on this topic rather
than helping to resolve it. Even after mentioning these
recommendations, articles published in 2014 refer to the
reporting of IF by clinicians as “currently a subject of in-
tense debate” [52], “one of the current, contentious de-
bates” [73], or state that “there remains strong debate”
[56] and an “ongoing discussion on how to best proceed
with incidental findings” [75]. Malhotra et al. [42] specif-
ically mention that “the methods of providing [incidental
findings] to patients are not entirely clear, although
some recommendations have recently been made by the
American College of Medical Genetics and Genomics”.
Even in 2015, this is still considered to be a “current de-
bate” by Goldberg et al. [76], and Bender state that the
discussion of this topic “will undoubtedly continue” [77].
This uncertainty on how to define and report IF is de-
scribed as the justification for using targeted testing over
WES and more generally NGS in certain clinical contexts,
such as hematology [46] or for heart diseases [78]. The
challenge of IF even leads Lohman et al. [75] to refer to
WES and WGS as a”curse” as well as a”blessing”.
From 2011 to 2015, we noted a steady increase in the
proportion of selected articles discussing the challenge
of IF. Indeed, it rose from 46.2 % of articles published in
2011, to 75 % in 2015. This trend is opposed to that of
the proportion of articles discussing VUS, as displayed
in Fig. 5. Since the total number of selected articles pub-
lished per year is variable and relatively small, it is diffi-
cult to attest the significance of this trend. However, we
can make the following hypothesis: as software tools and
reference databases have improved, the interpretation of
WES variants has become less and less challenging for
technology users. On the other hand, the publication of
recommendations and guidelines in the USA [16],
Canada [23] and Europe [22] has polarized the debate
on the challenge of identification, classification and
reporting of IF, which may help explain why it was in-
creasingly mentioned in our selection of articles.
Cost and reimbursement
The challenge of WES’ cost and of test reimbursement is
reported in 49 % of articles (72). It includes a number of
sub-challenges along the WES data trajectory from pro-
duction to analysis and interpretation. Although they do





















2011 (13) 2012 (31) 2013 (42) 2014 (46) 2015 (12)
Interpretation of variants, VUS Incidental findings
Fig. 5 Proportion of articles addressing VUS and IF per year. In parenthesis next to the year of publication of articles, we indicated the total
number of selected articles published that year
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in 2014 and 2015 consider that WES is still too expen-
sive to be implemented as a standard of care in different
contexts such as epilepsy [54], acute myeloid leukemia
[52], axonopathies [79], sudden unexplained death [80]
and cardiac arrhythmia [78]. Since sequencing costs have
fallen drastically over time, it is notable that even in
2014 some authors consider that it is the sequencing it-
self that is too expensive [37, 81–83]. Other justifications
for the high price of these tests mentioned by authors
include the cost of data storage [84] and necessary
Sanger validation of WES results [50]. Data interpret-
ation in general is another reason provided to explain
the higher costs of WES compared to more targeted
sequencing [50, 85, 86]. Focusing on the possibility of
using WES in newborn screening, Beckmann et al. [87],
provide a more detailed assessment of costs which leads
them to conclude that “From a cost perspective,
generalization of this practice with current procedures
would entail a monumental effort that is likely to ruin
our social healthcare programs.” Those “important so-
cial, economic, and human costs” are linked to the in-
creased time clinicians would have to spend interpreting
and reporting WES results to patients and families.
The large-scale application of WES in the clinic will
only be possible if it is integrated fully into the
healthcare system as a standard of care for certain
conditions. This requires a thorough economic evalu-
ation of possible funding sources and strategies to re-
imburse this sort of analysis. According to many
articles from the USA, UK and Germany published
after 2014, cost assessment analysis and economic
evaluation studies still have to be performed in order
to formally establish the relative cost efficiency of
WES compared to other techniques [34, 38, 65, 73,
75, 88, 89]. The need for private insurance providers to
reimburse these tests is reported as one of the key ele-
ments standing in the way of clinical implementation of
WES on a larger scale, especially in the USA [39, 51, 89–
91]. Not only will the clinical utility [62] and cost effi-
ciency of these tests have to be proven, but insurance
companies and the public healthcare system will have to
organise the administrative infrastructure needed to reim-
burse those tests, such as by creating ‘new billing codes’
[39, 92].
Discussion
Our methodology carried a number of limitations. The
first challenge of our approach is that we tried to iden-
tify elements in publications which had a different pri-
mary focus. Indeed, we were looking to identify sections
describing unsolved implementation challenges in publi-
cations focusing on the description of the actual use of
WES in a clinical context. This made the task of identi-
fying those sections more difficult, and may have
resulted in failure to identify a number of articles. In-
deed, the relevant sections of the selected articles were
extremely diverse, ranging from a few words to full titled
sections. Another issue which could possibly have led us
to miss relevant publications was our choice of search
terms. Our keyword combination of (“Clinical applica-
tion” OR “Medical application” OR “Healthcare” OR
“Clinical care” OR “Medical care” OR “Clinical practice”
OR “Clinical diagnostic” OR “Medical practice”) may
have lacked specificity, leading us to overlook relevant
articles because of the very high number of hits we
obtained. In addition, the process of filtering all 2095
articles was very lengthy. Since the date at which we per-
formed the search, a number of potentially relevant arti-
cles have been published. In addition, the regulatory
landscape of clinical WES has evolved, with the publica-
tion of a number of guidelines and recommendations
which will significantly impact this field, notably in
Europe [93], and the USA [94–97]. The speed, efficiency
and reproducibility of the data filtering process could be
significantly enhanced if this process was partly auto-
mated. However, to our knowledge there is no open ac-
cess software tool that could have performed the search
based on keywords and context generation more effi-
ciently than we did. One other limitation lies in the
combination of quantitative and qualitative approaches
we used to analyze all 23 challenges identified in 147 se-
lected articles. This was a relatively small sample size in
which to obtain significant differences between sub-
groups of articles. On the other hand, it was a high
number of articles to analyze thoroughly, which is why
we decided to analyze only the challenges that were
most reported by authors. We believe this combination
of qualitative and quantitative methodologies is key to
making informed policy decisions based on the latest
body of evidence regarding technologies such as WES.
Conclusions
A number of challenges need to be resolved before
whole exome sequencing can be implemented as a
standard of care in the clinical setting. Through this sys-
tematic review of the literature, we could identify as
many as 23 of these challenges. The three challenges
that were most consistently reported by technology users
were that of incidental findings, variants of unknown
significance, and the cost of the technology. Although a
small number of challenges, notably communication
with patients, education of clinicians, and patients’ turn-
around time, were reported differently in articles focus-
ing on cancer, rare diseases or all diseases, and in
articles from different countries, most challenges were
discussed similarly across diseases and countries (data
not shown). WES is already used in the clinical setting,
and may soon be considered the standard of care for
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specific medical conditions, most notably for the identi-
fication of mutations contributing to rare genetic dis-
eases. Clinics in the USA [41], France [98] and the
Netherlands [99] already report promising results from
the systematic use of NGS in hundreds of patients. Yet,
technology users are calling for certain standards and
guidelines to be published before this technology
replaces more focused approaches such as gene panels
sequencing. In addition, it is clear that a number of in-
frastructural adjustments will have to be made for
clinics to store, process and analyze the amounts of
data produced by WES. The interpretation of this data
requires specially trained staff, and patients and families
must also be adequately prepared to deal with WES test
results. Some intermediary solutions may be found,
such as the one suggested by Topper et al.: “In the near
term, we suggest that many of these technical and eth-
ical challenges may be alleviated by a targeted analysis
approach, in which the full exome sequence is gener-
ated in patients, but analysis is initially limited to those
genes already known to play a role in the presenting
disorder” [60].
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